US targets Novo Nordisk’s Ozempic and Wegovy for Medicare price talks | Reuters

Excerpt from Reuters: “Novo Nordisk’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Other drugs on the list include Pfizer’s cancer drugs Ibrance and Xtandi, GSK’s asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva’s Huntington’s disease treatment Austedo and Abbvie’s irritable bowel syndrome drug Linzess.” Read more.

Scientists want to create an AI virtual cell | The Week

Excerpt from The Week: “Studying the cell is a difficult and time-consuming process, but scientists have pinpointed generative AI as a potential way to make it easier. The idea is to develop an AI virtual cell that would behave the same way a real cell does. This would allow researchers to do medical experiments on the computer rather than on a live cell, making the process more efficient and more affordable.” Read more.

US FDA approves Amgen’s colorectal cancer therapy | Reuters

Excerpt from Reuters: “The U.S. Food and Drug Administration approved Amgen’s combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

Amgen’s Lumakras in combination with Vectibix was approved to treat adult patients whose cancer has spread to other parts of the body despite receiving chemotherapy, the health regulator said.

The FDA also approved Netherlands-based Qiagen’s companion diagnostic device to identify patients eligible for the combination treatment.” Read more.